Antidotes and poisoning medical products / 2024-2025
Finnish Institute for Health and Welfare · koko Suomi
Perustiedot
- Hankkija
- Finnish Institute for Health and Welfare, Y-tunnus 2229500-6
- Toteutuspaikka
- koko Suomi
- Hankintalaji
- Tavarahankinta
- Menettely
- Avoin menettely, EU-hankinta
- Ilmoituksen tyyppi
- Jälki-ilmoitus
- Sopimusten kokonaisarvo
- 1 € (alv 0 %)
- Erät
- 13 erää
- Pääasiallinen CPV
- 33690000 Muut lääkkeet
- Lisäkoodit: 33600000, 33692510
- Sopimuskausi
- 17 kuukautta
- Julkaistu
- 23.5.2024
Hankinnan tulos
| Erä | Voittaja | Sopimusarvo | Tarjouksia | Päätös |
|---|---|---|---|---|
| Erä 1: LOT 1: Dimercaptopropane sulfonate (DMPS) 100 mg tablets/capsules | HEYL | ei ilmoitettu | 1 | |
| Erä 2: LOT 2: Prussian blue, i.e. Iron(III) hexacyanoferrate(II) 500 mg tablets/capsules | Ei voittajaa: Muu | – | ei ilmoitettu | |
| Erä 3: LOT 3: Succimer (Dimercaptosuccinic acid, DMSA) 200 mg tablets/capsules | Serb | ei ilmoitettu | ei ilmoitettu | |
| Erä 4: LOT 4: Dimercaptopropane sulfonate (DMPS) 50 mg/ml (5 ml per vial/ampoule) | HEYL | ei ilmoitettu | ei ilmoitettu | |
| Erä 5: LOT 5: Calcium trisodium pentetate (Ca-DTPA) 1 g / 5 ml (5 ml per vial/ampoule) | HEYL | ei ilmoitettu | ei ilmoitettu | |
| Erä 6: LOT 6: Zinc trinatrium pentetate (Zn-DTPA) 1055 mg / 5 ml (5 ml per vial/ampoule) | HEYL | ei ilmoitettu | ei ilmoitettu | |
| Erä 7: LOT 7: Obidoxime 250 mg/ml (1 ml per vial/ampoule) | Serb | ei ilmoitettu | ei ilmoitettu | |
| Erä 8: LOT 8: Pralidoxime 2 g / 100 ml (100 ml per vial/ampoule) | Serb | ei ilmoitettu | ei ilmoitettu | |
| Erä 9: LOT 9: Hydroxocobalamin 5 g (5 g per vial/ampoule) | Ei voittajaa: Muu | – | ei ilmoitettu | |
| Erä 10: LOT 10: Fomepizole 5 mg/ml (20 ml per vial/ampoule) | Serb | ei ilmoitettu | ei ilmoitettu | |
| Erä 11: LOT 11: Calcium edetate (Ca-EDTA) 50 mg/ml (10 ml per vial/ampoule) | Serb | ei ilmoitettu | ei ilmoitettu | |
| Erä 12: LOT 12: Calcium gluconate 100 mg/ml (10 ml per vial/ampoule) | Ei voittajaa: Tarjouksia, osallistumishakemuksia tai hankkeita ei saatu | – | 0 | |
| Erä 13: LOT 13: Silver sulfadiazine 10 mg/g (50 g - 100 g per tube/container) | Ei voittajaa: Tarjouksia, osallistumishakemuksia tai hankkeita ei saatu | – | 0 |
Voittajista näytetään nimi ja Y-tunnus. ”Ei ilmoitettu” tarkoittaa, ettei ilmoituksessa ole tätä tietoa erälle tai sopimukselle.
Ilmoituksen teksti
Alkuperäinen teksti Hilmasta, muuttamattomanaThe Scope of the procurement is Antidotes and poisoning medical products to the rescEU project. The Scope of procurement is described in more detail in the Call for tenders and its Annexes.
The procurement is divided in thirteen (13) lots. Tender may be submitted for one or several lots.
- LOT 1: Dimercaptopropane sulfonate (DMPS) 100 mg tablets/capsules
- LOT 2: Prussian blue, i.e. Iron(III) hexacyanoferrate(II) 500 mg tablets/capsules
- LOT 3: Succimer (Dimercaptosuccinic acid, DMSA) 200 mg tablets/capsules
- LOT 4: Dimercaptopropane sulfonate (DMPS) 50 mg/ml (5 ml per vial/ampoule)
- LOT 5: Calcium trisodium pentetate (Ca-DTPA) 1 g / 5 ml (5 ml per vial/ampoule)
- LOT 6: Zinc trinatrium pentetate (Zn-DTPA) 1055 mg / 5 ml (5 ml per vial/ampoule)
- LOT 7: Obidoxime 250 mg/ml (1 ml per vial/ampoule)
- LOT 8: Pralidoxime 2 g / 100 ml (100 ml per vial/ampoule)
- LOT 9: Hydroxocobalamin 5 g (5 g per vial/ampoule)
- LOT 10: Fomepizole 5 mg/ml (20 ml per vial/ampoule)
- LOT 11: Calcium edetate (Ca-EDTA) 50 mg/ml (10 ml per vial/ampoule)
- LOT 12: Calcium gluconate 100 mg/ml (10 ml per vial/ampoule)
- LOT 13: Silver sulfadiazine 10 mg/g (50 g - 100 g per tube/container)
The contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
The contract period shall enter into force once the contract has been signed by contracting parties and expires when all contractual duties of the contract have been performed.
Call for Tenders, Annexes:
Annex 1 Scope of the procurement
Annex 1.1 Minimum requirements
Annex 2 Contract
Annex 3 Security annex
Annex 4 Description of the Handi service
Annex 5 JYSE 2014 SUPPLIES (updated version of April 2022)
Annex 6 Estimated quantity (restricted, TL IV)
Annex 7 Confidentiality commitment
Please note that the numbering of the annexes differs between the Contract and the Call for Tenders.
Lisätiedot
The availability for the Annex 6 is restricted to security classification level IV, TL IV. THL will send the restricted Annex 6 to a representative of the tenderer via encrypted email after THL has received the signed confidentiality commitment (Annex 7). Confidentiality commitment shall be signed by a legal representative of tenderer. Confidentiality commitment shall be sent to the email address kirjaamo@thl.fi with the subject line "CONFIDENTIALITY COMMITMENT - THL/5139/2.02.06/2023 / Antidotes and poisoning medical products / 2024-2025". The message must contain name of the tenderer and email address to which the restricted Annex 6 is to be sent.
Erien kuvaukset
Erä 1: LOT 1: Dimercaptopropane sulfonate (DMPS) 100 mg tablets/capsules
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Dimercaptopropane sulfonate (DMPS) 100 mg
- Oral solid dosage forms
- Active pharmaceutical ingredient: Dimercaptopropane sulfonate (DMPS)
- Strength: 100 mg
- Pharmaceutical form: tablets/capsules.
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 2: LOT 2: Prussian blue, i.e. Iron(III) hexacyanoferrate(II) 500 mg tablets/capsules
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Prussian blue, i.e. Iron(III) hexacyanoferrate(II) 500 mg tablets/capsules
- Oral solid dosage forms
- Active pharmaceutical ingredient: Prussian blue, i.e. Iron(III) hexacyanoferrate(II)
- Strength: 500 mg
- Pharmaceutical form: tablets/capsules.
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 3: LOT 3: Succimer (Dimercaptosuccinic acid, DMSA) 200 mg tablets/capsules
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Succimer (Dimercaptosuccinic acid, DMSA) 200 mg tablets/capsules
- Oral solid dosage forms
- Active pharmaceutical ingredient: Succimer (Dimercaptosuccinic acid, DMSA)
- Strength: 200 mg
- Pharmaceutical form: tablets/capsules.
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 4: LOT 4: Dimercaptopropane sulfonate (DMPS) 50 mg/ml (5 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Dimercaptopropane sulfonate (DMPS) 50 mg/ml (5 ml per vial/ampoule)
- Parenteral product (intravenous administration)
- Active pharmaceutical ingredient: Dimercaptopropane sulfonate (DMPS)
- Strength: 50 mg/ml
- Container size: 5 ml per vial/ampoule.
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 5: LOT 5: Calcium trisodium pentetate (Ca-DTPA) 1 g / 5 ml (5 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Calcium trisodium pentetate (Ca-DTPA) 1 g / 5 ml (5 ml per vial/ampoule)
- Parenteral product (intravenous administration)
- Active pharmaceutical ingredient: Calcium trisodium pentetate (Ca-DTPA)
- Strength: 1 g / 5 ml
- Container size: 5 ml per vial/ampoule.
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 6: LOT 6: Zinc trinatrium pentetate (Zn-DTPA) 1055 mg / 5 ml (5 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Zinc trinatrium pentetate (Zn-DTPA) 1055 mg / 5 ml (5 ml per vial/ampoule)
- Parenteral product (intravenous administration)
- Active pharmaceutical ingredient: Zinc trinatrium pentetate (Zn-DTPA)
- Strength: 1055 mg / 5 ml
- Container size: 5 ml per vial/ampoule.
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 7: LOT 7: Obidoxime 250 mg/ml (1 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Obidoxime 250 mg/ml (1 ml per vial/ampoule)
- Parenteral product (intravenous administration)
- Active pharmaceutical ingredient: Obidoxime
- Strength: 250 mg/ml
- Container size: 1 ml per vial/ampoule.
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 8: LOT 8: Pralidoxime 2 g / 100 ml (100 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Pralidoxime 2 g / 100 ml (100 ml per vial/ampoule)
- Parenteral product (intravenous administration)
- Active pharmaceutical ingredient: Pralidoxime
- Strength: 2 g / 100ml
- Container size: 100 ml per vial/ampoule.
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 9: LOT 9: Hydroxocobalamin 5 g (5 g per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Hydroxocobalamin 5 g (5 g per vial/ampoule)
- Parenteral product (intravenous administration)
- Active pharmaceutical ingredient: Hydroxocobalamin
- Strength: 5 g
- Container size: 5 g per vial/ampoule.
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 10: LOT 10: Fomepizole 5 mg/ml (20 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Fomepizole 5 mg/ml (20 ml per vial/ampoule)
- Parenteral product (intravenous administration)
- Active pharmaceutical ingredient: Fomepizole
- Strength: 5 mg/ml
- Container size: 20 ml per vial/ampoule.
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 11: LOT 11: Calcium edetate (Ca-EDTA) 50 mg/ml (10 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Calcium edetate (Ca-EDTA) 50 mg/ml (10 ml per vial/ampoule)
- Parenteral product (intravenous administration)
- Active pharmaceutical ingredient: Calcium edetate (Ca-EDTA)
- Strength: 50 mg/ml
- Container size: 10 ml per vial/ampoule.
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 12: LOT 12: Calcium gluconate 100 mg/ml (10 ml per vial/ampoule)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Calcium gluconate 100 mg/ml (10 ml per vial/ampoule)
- Parenteral product (intravenous administration)
- Active pharmaceutical ingredient: Calcium gluconate
- Strength: 100 mg/ml
- Container size: 10 ml per vial/ampoule.
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 13: LOT 13: Silver sulfadiazine 10 mg/g (50 g - 100 g per tube/container)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Silver sulfadiazine 10 mg/g (50 g - 100 g per tube/container)
- Cream on the skin for topical use
- Active pharmaceutical ingredient: Silver sulfadiazine
- Strength: 10 mg/g
- Container size: 50 g - 100 g per tube/container.
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erät
| Erä | Nimi | Ammattiala | Arvioitu arvo | CPV |
|---|---|---|---|---|
| 1 | LOT 1: Dimercaptopropane sulfonate (DMPS) 100 mg tablets/capsules | – | – | 33690000, 33600000 |
| 2 | LOT 2: Prussian blue, i.e. Iron(III) hexacyanoferrate(II) 500 mg tablets/capsules | – | – | 33690000, 33600000 |
| 3 | LOT 3: Succimer (Dimercaptosuccinic acid, DMSA) 200 mg tablets/capsules | – | – | 33690000, 33600000 |
| 4 | LOT 4: Dimercaptopropane sulfonate (DMPS) 50 mg/ml (5 ml per vial/ampoule) | – | – | 33692510, 33600000 |
| 5 | LOT 5: Calcium trisodium pentetate (Ca-DTPA) 1 g / 5 ml (5 ml per vial/ampoule) | – | – | 33692510, 33600000 |
| 6 | LOT 6: Zinc trinatrium pentetate (Zn-DTPA) 1055 mg / 5 ml (5 ml per vial/ampoule) | – | – | 33692510, 33600000 |
| 7 | LOT 7: Obidoxime 250 mg/ml (1 ml per vial/ampoule) | – | – | 33692510, 33600000 |
| 8 | LOT 8: Pralidoxime 2 g / 100 ml (100 ml per vial/ampoule) | – | – | 33692510, 33600000 |
| 9 | LOT 9: Hydroxocobalamin 5 g (5 g per vial/ampoule) | – | – | 33692510, 33600000 |
| 10 | LOT 10: Fomepizole 5 mg/ml (20 ml per vial/ampoule) | – | – | 33692510, 33600000 |
| 11 | LOT 11: Calcium edetate (Ca-EDTA) 50 mg/ml (10 ml per vial/ampoule) | – | – | 33692510, 33600000 |
| 12 | LOT 12: Calcium gluconate 100 mg/ml (10 ml per vial/ampoule) | – | – | 33692510, 33600000 |
| 13 | LOT 13: Silver sulfadiazine 10 mg/g (50 g - 100 g per tube/container) | – | – | 33690000, 33600000 |
Hankinnan vaiheet
-
Tarjouspyyntö julkaistiin, määräaika 24.11.2023 klo 12.00.
-
Jälki-ilmoitustämä ilmoitus
Voittajat: HEYL ja Serb.